Study to Evaluate the Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU
Status:
Completed
Trial end date:
2021-01-13
Target enrollment:
Participant gender:
Summary
This is a Phase 3 open-label extension study enrolling approximately 40 adult patients with
PKU who were previously treated with pegvaliase in Studies PAL-003 or 165-302. The study is
designed to evaluate the long-term safety and efficacy of pegvaliase administered at doses >
40 mg/day to 60 mg/day